In this issue:
- Ipilimumab-nivolumab in molecularly selected CRPC
- Perioperative durvalumab with neoadjuvant chemotherapy in operable MIBC
- Pembrolizumab for advanced urothelial carcinoma
- Tivozanib ± nivolumab after ICI for RCC
- First-line nivolumab ipilimumab vs. sunitinib for advanced RCC
- Long-term response to nivolumab in previously treated advanced RCC
- Impact of treating residual disease after immunotherapy on CR in metastatic RCC
- Avelumab + intermittent axitinib in previously untreated metastatic RCC
- Papillary RCC: outcomes after first-line immunotherapy vs. TKIs
- Effect of corticosteroids for immune-related adverse events on ICI efficacy
Please login below to download this issue (PDF)